Stan Crooke on Ultra Rare Disease Drugs
Biotech titan [...]
n-Lorem 1 Year Anniversary
2 minutes
IND Submissions for Individualized Antisense Oligonucleotide Drug Products: Administrative and Procedural Recommendations
U.S. Department of Health and Human Services
Food and Drug Administration
Center for Drug Evaluation and Research (CDER)
Download PDF
Antisense Drug Discovery and Development Technology Considered in a Pharmacological Context
Crooke, S.T., Liang, X.H., Crooke R.M., Baker, B.F., Geary, R.S.
The Interaction of Phosphorothioate Containing RNA Targeted Drugs with Proteins is a Critical Determinant of The Therapeutic Effects of These Agents
Crooke, S.T., Seth., P.P., Vickers, T.A., Liang, X.H.
How you can help provide experimental ASO treatments to patients with ultra-ultra-rare diseases.
Over the last three years, [...]
Phosphorothioate modified oligonucleotide–protein interactions
Crooke, S.T., Vickers, T.A., Liang, X.H.
